mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Antidepressant Action of Ketamine: In contrast to the weeks or months of treatment required for standard antidepressant medication, ketamine administration produces an antidepressant response within 4 to 6 hours in depressed patients. What lies behind the rapid actions of ketamine? Li et al. (p. 959 ; see the Perspective by Cryan and O'Leary ) found that ketamine administration resulted in fast activation of mammalian target of rapamycin (mTOR) signaling and increased levels of synaptic proteins in the rat prefrontal cortex. Ketamine rapidly increased the density and function of the dendritic spines of layer V pyramidal neurons in the prefrontal cortex. Thus, the behavioral actions of ketamine in models of depression and antidepressant response are dependent on mTOR signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies have suggested that ketamine can increase the synthesis of synaptic proteins through BDNF signaling dependent on the activate protein kinase B (Akt) and mammalian target of rapamycin complex 1 (mTORC1) signaling cascades. 378 , 379”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [378]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Esmethadone can also alleviate neural dysfunction linked to symptoms of depression by boosting the synapse and spine density and restoring spinogenesis, in addition to correcting depressive-like behaviors in animal models of depression. 378 , 477”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [378]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We have found that infusion of rapamycin into the medial PFC, but not the dorsal striatum, blocks the effects of systemic ketamine administration (6).”
From Synaptic Dysfunction in Depression: Potential Therapeutic Targets (2012) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ketamine rapidly and transiently increases glutamate transmission in the PFC, possibly via inhibition of tonically active GABAergic inter-neurons, and the resulting burst of glutamate is thought to underlie ketamine induction of synapto-genesis (6, 7).”
From Synaptic Dysfunction in Depression: Potential Therapeutic Targets (2012) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A single dose of ketamine increases BDNF release and stimulates mTORC1 signaling, which leads to increased levels of synaptic proteins (i.e., GluR1, PSD95, and synapsin 1) and increased number and function of synapses in the PFC 4,22,35 .”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [35]
Experimental — accuracy not yet measured
42 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Rajkowska, G., Miguel-Hidalgo, J. J., Wei, J., Dilley, G., Pittman, S. D., Meltzer, H. Y., Overholser, J. C., Roth, B. L., & Stockmeier, C. A. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00041-4 · Cited by 1,477
mTOR signaling: At the crossroads of plasticity, memory and disease
Hoeffer, C. A., & Klann, E. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2009.11.003 · Cited by 1,128
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Preskorn, S. H., Baker, B., Kolluri, S., Menniti, F. S., Krams, M., & Landen, J. W. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31818a6cea · Cited by 518
Functional neuroimaging studies of depression: The anatomy of melancholia
Drevets, W. C. (1998) · Annual Review of Medicine · doi:10.1146/annurev.med.49.1.341 · Cited by 500
Liu, R.-J., & Aghajanian, G. K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706679105 · Cited by 346
Self-citation
Cited by
Items 301–400 of 1,062
Cavalleri, L., Merlo Pich, E., Millan, M. J., Chiamulera, C., Kunath, T., Spano, P. F., & Collo, G. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.241 · Cited by 156
“is thought to preferentially activate -amino-3-hydroxy-5-methyl-4isoxazolepropionic acid receptors (AMPAR)(8,11,12) that promote synthesis and release of Brain Derived Neurotrophic Factor (BDNF),(13,14) which in turn drives structural plasticity mediated by protein synthesis and dendrite outgrowth via activation of m…”
BackgroundInfluentialCaddy, C., Giaroli, G., White, T. P., Shergill, S. S., & Tracy, D. K. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125313507739 · Cited by 138
“A recent rat study showed increases in mTOR phosphorylation and activation within half an hour of ketamine administration, followed by rapid increases in the density, maturation and function of prefrontal pyramidal neuron spines [Li et al. 2010].”
BackgroundTang, J., Xue, W., Xia, B., Ren, L., Tao, W., Chen, C., Zhang, H., Wu, R., Wang, Q., Wu, H., et al. (2015) · Scientific Reports · doi:10.1038/srep13573 · Cited by 149
Rădulescu, I., Drăgoi, A., Trifu, S., & Cristea, M. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10565 · Cited by 121
“It was confirmed that chronic ketamine intake upregulates dopamine synthesis and levels (88).”
Learned helplessness: unique features and translational value of a cognitive depression model
Vollmayr, B., & Gass, P. (2013) · Cell and Tissue Research · doi:10.1007/s00441-013-1654-2 · Cited by 155
“…molecular mechanisms underlying this antidepressant response to be deciphered, e.g., the involvement of mammalian target of rapamycin (mTOR)-dependent synapse formation and deactivation of eukaryotic elongation factor 2 resulting in increased translation of BDNF (Autry et al. 2011; Li et al. 2010).”
BackgroundGoffer, Y., Xu, D., Eberle, S. E., D'amour, J., Lee, M., Tukey, D., Froemke, R. C., Ziff, E. B., & Wang, J. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.2454-13.2013 · Cited by 141
“…important role in depression (Hashimoto, 2009; Skolnick et al., 2009; Sanacora et al., 2012), and pharmacologic agents that increase transmission through AMPA receptors have been shown to have antidepressant effects (Skolnick, 2008; Machado-Vieira et al., 2009; Li et al., 2010a; Wang et al., 2011).”
BackgroundLi, C., Xiao, L., Liu, X., Yang, W., Shen, W., Hu, C., Yang, G., & He, C. (2013) · Glia · doi:10.1002/glia.22469 · Cited by 138
“, 2009) which also mediated various effect of NMDAR in neuronal cells (Li et al., 2010; Swiech et al., 2008; Wang et al., 2011; Wang et al., 2007).”
BackgroundInfluentialReduced global functional connectivity of the medial prefrontal cortex in major depressive disorder
Murrough, J. W., Abdallah, C. G., Anticevic, A., Collins, K. A., Geha, P., Averill, L. A., Schwartz, J., DeWilde, K. E., Averill, C., Jia‐Wei Yang, G., et al. (2016) · Human Brain Mapping · doi:10.1002/hbm.23235 · Cited by 153
“Repeated stress exposure in rodents alters synaptic homeostasis and results in reductions in synaptic plasticity and decreased synaptic connectivity within the medial PFC, which drive depressive behavior [Li et al., 2010].”
BackgroundCultural Differences and Information Technology Acceptance
Zakour, A. B. (2004) · Cited by 155
( 2R,6R )-hydroxynorketamine exerts mGlu 2 receptor-dependent antidepressant actions
Zanos, P., Highland, J. N., Stewart, B. W., Georgiou, P., Jenne, C. E., Lovett, J., Morris, P. J., Thomas, C. J., Moaddel, R., Zarate, C. A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819540116 · Cited by 152
Li, C., Chen, M., Lin, W., Hong, C., Yang, B., Liu, R., Tu, P., & Su, T. (2016) · Human Brain Mapping · doi:10.1002/hbm.23085 · Cited by 152
Self-citationMa, Z., Zang, T., Birnbaum, S. G., Wang, Z., Johnson, J. E., Zhang, C.-L., & Parada, L. F. (2017) · Nature Communications · doi:10.1038/s41467-017-01709-8 · Cited by 141
Esketamine for treatment resistant depression
Swainson, J., Thomas, R. K., Archer, S., Chrenek, C., MacKay, M.-A., Baker, G., Dursun, S., Klassen, L. J., Chokka, P., & Demas, M. L. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1640604 · Cited by 151
A brief history of antidepressant drug development: from tricyclics to beyond ketamine
Pereira, V. S., & Sato, V. (2018) · Acta Neuropsychiatrica · doi:10.1017/neu.2017.39 · Cited by 153
“Posteriorly, it was demonstrated that the antidepressant-like effects of different NMDA antagonists as ketamine, Ro 25-6981 and LY 235959 are blocked by mTOR inhibition in the prefrontal cortex of rats exposed to the forced swim test (80,82,83).”
InfluentialDwyer, J. M., & Duman, R. S. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.11.011 · Cited by 132
“Ketamine also increases signaling through ERK and Akt (51), two upstream mTOR regulators that are activated by neurotrophic factors such as BDNF.”
InfluentialSelf-citationThe role of vitamin C in stress-related disorders
Moritz, B., Schmitz, A. E., Rodrigues, A. L. S., Dafre, A. L., & Cunha, M. P. (2020) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2020.108459 · Cited by 126
Antidepressant actions of ketamine: from molecular mechanisms to clinical practice
Monteggia, L. M., & Zarate, C. (2015) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2014.12.004 · Cited by 149
Sustained remission from depressive-like behavior depends on hippocampal neurogenesis
Mateus-Pinheiro, A., Pinto, L., Bessa, J. M., Morais, M., Alves, N. D., Monteiro, S., Patrício, P., Almeida, O. F. X., & Sousa, N. (2013) · Translational Psychiatry · doi:10.1038/tp.2012.141 · Cited by 149
“demonstrating the fast behavioral actions of ketamine, an NMDA receptor antagonist, support this view.(35) However, we also reveal, for the first time, the occurrence of persistent”
BackgroundGABAergic Control of Depression-Related Brain States
Luscher, B., & Fuchs, T. (2015) · Advances in Pharmacology · doi:10.1016/bs.apha.2014.11.003 · Cited by 149
“…synapses (Kang et al., 2012), ketamine-induced antidepressant effects involve an mTor-dependent mechanim of synaptogenesis, including rapid induction of spine fomation and increased function of glutamatergic synapses (reviewed in R. S. Duman & Li, 2012; N. Li et al., 2010; N. Li et al., 2011).”
BackgroundLaminar and Cellular Distribution of Monoamine Receptors in Rat Medial Prefrontal Cortex
Santana, N., & Artigas, F. (2017) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2017.00087 · Cited by 130
“Likewise, the fast antidepressant actions of ketamine are associated to an activation of layer V pyramidal neurons in the mPFC (Li et al., 2010).”
BackgroundEsterlis, I., DellaGioia, N., Pietrzak, R. H., Matuskey, D., Nabulsi, N., Abdallah, C. G., Yang, J., Pittenger, C., Sanacora, G., Krystal, J. H., et al. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.58 · Cited by 148
Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse
Korpi, E. R., den Hollander, B., Farooq, U., Vashchinkina, E., Rajkumar, R., Nutt, D. J., Hyytiä, P., & Dawe, G. S. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010967 · Cited by 148
“Furthermore, the brain growth-promoting and limiting responses to injury are blunted and dysregulated in elderly (22–24 months) versus adult (2–4 months) rats (Li and Carmichael, 2006; Li et al., 2010b).”
BackgroundPotentiation of μ‐opioid receptor‐mediated signaling by ketamine
Gupta, A., Devi, L. A., & Gomes, I. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07361.x · Cited by 132
“…it also exhibits non-NMDA-mediated effects by modulating the activity of nicotinic (Scheller et al. 1996), muscarinic (Hustveit et al. 1995), opioid (Smith et al. 1980; Finck and Ngai 1982; Hustveit et al. 1995; Hirota et al. 1999) as well as AMPA receptors (Li et al. 2010; Zarate et al. 2010).”
BackgroundKetamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature
Drozdz, S. J., Goel, A., McGarr, M. W., Katz, J. D., Ritvo, P., Mattina, G. F., Bhat, V., Diep, C., & Ladha, K. S. (2022) · Journal of Pain Research · doi:10.2147/jpr.s360733 · Cited by 151
“In animal models, acute ketamine administration has been shown to activate several downstream signalling cascades that include the mammalian target of rapamycin (mTOR), glycogen synthase kinase-3 (GSK3), and elongation factor 2 (eEF2) kinase, which have been implicated in neuroplasticity mechanisms and the pathophysio…”
BackgroundGeorgiou, P., Zanos, P., Mou, T.-C. M., An, X., Gerhard, D. M., Dryanovski, D. I., Potter, L. E., Highland, J. N., Jenne, C. E., Stewart, B. W., et al. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01146-x · Cited by 134
Self-citationTanaka, K., Furuyashiki, T., Kitaoka, S., Senzai, Y., Imoto, Y., Segi-Nishida, E., Deguchi, Y., Breyer, R. M., Breyer, M. D., & Narumiya, S. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5952-11.2012 · Cited by 131
“rapid antidepressive action of ketamine (Li et al., 2010).”
BackgroundAn emerging role for TOR signaling in mammalian tissue and stem cell physiology
Russell, R. C., Fang, C., & Guan, K.-L. (2011) · Development · doi:10.1242/dev.058230 · Cited by 130
“…ketamine, a N-methyl-D-aspartic acid (NMDA) receptor antagonist, currently in clinical trials, rapidly activates the TORC1 pathway and is repressed by rapamycin, underscoring a crucial role for TORC1 in regulating appropriate signaling by upstream cellular cues in neuron function (Li et al., 2010).”
BackgroundHu, Y.-D., Xiang, Y.-T., Fang, J.-X., Zu, S., Sha, S., Shi, H., Ungvari, G. S., Correll, C. U., Chiu, H. F. K., Xue, Y., et al. (2016) · Psychological Medicine · doi:10.1017/s0033291715002159 · Cited by 146
“Furthermore, blockadeofmTORsignalingblockedketamine induction of synaptogenesis and behavioral responses in animalmodels of depression (Li et al. 2010).”
BackgroundChandran, A., Iyo, A. H., Jernigan, C. S., Legutko, B., Austin, M. C., & Karolewicz, B. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.08.001 · Cited by 137
“…for the rapid and sustained antidepressant-like effects of ketamine (an NMDA receptor antagonist) and LY341495 (a metabotropic glutamate receptor subtype 2/3 antagonist) in animal screening procedures (Dwyer et al., 2012; Koike et al., 2011; Li et al., 2010, 2011; reviewed by Hashimoto, 2011).”
BackgroundRenard, J., Loureiro, M., Rosen, L. G., Zunder, J., de Oliveira, C., Schmid, S., Rushlow, W. J., & Laviolette, S. R. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.3387-15.2016 · Cited by 131
“Several clinical and preclinical studies have linked dysregulated mTOR signaling with neurodevelopmental and neuropsychiatric disorders, such as depression and schizophrenia (Li et al., 2010; Jernigan et al., 2011; BonitoOliva et al., 2013; Gururajan and van den Buuse, 2014; Liu et al., 2015).”
BackgroundKrystal, J. H., Abdallah, C. G., Averill, L. A., Kelmendi, B., Harpaz-Rotem, I., Sanacora, G., Southwick, S. M., & Duman, R. S. (2017) · Current Psychiatry Reports · doi:10.1007/s11920-017-0829-z · Cited by 145
Self-citationFrom Gene to Behavior: L-Type Calcium Channel Mechanisms Underlying Neuropsychiatric Symptoms
Kabir, Z. D., Martínez-Rivera, A., & Rajadhyaksha, A. M. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0532-0 · Cited by 145
Ketamine: Mechanisms and Relevance to Treatment of Depression
Kim, J., Suzuki, K., Kavalali, E. T., & Monteggia, L. M. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-051322-120608 · Cited by 148
Milak, M. S., Proper, C. J., Mulhern, S. T., Parter, A. L., Kegeles, L. S., Ogden, R. T., Mao, X., Rodriguez, C. I., Oquendo, M. A., Suckow, R. F., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.83 · Cited by 144
“Linear mixed-effects models tested for: (1) effect of time point on POMS score with time point as a (categorical) fixed effect and subject as a random effect; (2) ketamine’s effect on log-transformed Glx/W and GABA/W levels, with subject as a random effect and each 13minute MRS frames as a fixed effect.”
MethodAntidepressant actions of ketamine engage cell-specific translation via eIF4E
Aguilar-Valles, A., De Gregorio, D., Matta-Camacho, E., Eslamizade, M. J., Khlaifia, A., Skaleka, A., Lopez-Canul, M., Torres-Berrio, A., Bermudez, S., Rurak, G. M., et al. (2021) · Nature · doi:10.1038/s41586-020-03047-0 · Cited by 144
GABA interneurons mediate the rapid antidepressant-like effects of scopolamine
Wohleb, E. S., Wu, M., Gerhard, D. M., Taylor, S. R., Picciotto, M. R., Alreja, M., & Duman, R. S. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85033 · Cited by 144
Self-citationKranaster, L., Kammerer-Ciernioch, J., Hoyer, C., & Sartorius, A. (2011) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-011-0205-7 · Cited by 147
“proposed that the rapid antidepressant action is modulated by the mammalian target of rapamycin (mTOR) pathway [27], and this may be a contributing factor for the smaller number of ECT sessions required by patients in the ketamine group.”
Review of Pharmacological Treatment in Mood Disorders and Future Directions for Drug Development
Li, X., Frye, M. A., & Shelton, R. C. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.198 · Cited by 146
“Animal studies of intracellular mechanisms of NMDA receptor antagonist have revealed that ketamine rapidly activates the mammalian target of rapamycin (mTOR) pathway in the prefrontal cortex, leading to increased levels of the postsynaptic proteins PSD95 and the GluR1 AMPA receptor subunit, and the presynaptic protein…”
BackgroundSelf-citationKetamine as a new treatment for depression: A review of its efficacy and adverse effects
Katalinic, N., Lai, R., Somogyi, A., Mitchell, P. B., Glue, P., & Loo, C. K. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867413486842 · Cited by 130
“For example, previous animal studies indicate that ketamine’s effects on glutamate transmission may show a complex inverted U-shape dose–response relationship (Li et al., 2010; Autry et al., 2011).”
BackgroundDakwar, E., Levin, F., Foltin, R. W., Nunes, E. V., & Hart, C. L. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.08.009 · Cited by 143
“a deficit typically characterized by depressive phenomena and prefrontal synaptic loss due to persistent, uncontrollable stress.(14-18,19-21) An important feature of drug dependence is compulsive drug use despite adverse consequences.”
Dysfunctional hippocampal activity affects emotion and cognition in mood disorders
Femenía, T., Gómez-Galán, M., Lindskog, M., & Magara, S. (2012) · Brain Research · doi:10.1016/j.brainres.2012.03.053 · Cited by 143
Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status
Henter, I. D., Park, L. T., & Zarate, C. A. (2021) · CNS Drugs · doi:10.1007/s40263-021-00816-x · Cited by 142
“As noted above, mTORC1 has been implicated as a downstream pathway connecting glutamate modulation with the induction of neuroplastic processes [32].”
BackgroundNeuroglialpharmacology: Myelination as a shared mechanism of action of psychotropic treatments
Bartzokis, G. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.01.015 · Cited by 142
“In addition to integrating myelination with nutrient and energy status described above, some neurotransmitter signaling mechanisms with antidepressant effects may act through mTOR-dependent mechanisms to integrate myelination with synaptogenesis (Duman et al., 2012; Li et al., 2010a).”
Tan, S., Wang, Y., Chen, K., Long, Z., & Zou, J. (2017) · Biological & Pharmaceutical Bulletin · doi:10.1248/bpb.b17-00131 · Cited by 142
Murrough, J. W., Burdick, K. E., Levitch, C. F., Perez, A. M., Brallier, J. W., Chang, L. C., Foulkes, A., Charney, D. S., Mathew, S. J., & Iosifescu, D. V. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.298 · Cited by 142
“Mechanistic studies in animals show that ketamine rapidly enhances synaptic plasticity at the level of prefrontal cortical neurons (Li et al, 2010, 2011), and is able to rapidly reverse stress-induced dendritic atrophy and behavioral depression in a brain-derived neurotrophic factor…”
BackgroundA pulse rapamycin therapy for infantile spasms and associated cognitive decline
Raffo, E., Coppola, A., Ono, T., Briggs, S. W., & Galanopoulou, A. S. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.03.021 · Cited by 139
“…pathwaymay increase the expression of glutamate receptors and excitatory synapses, leading to epilepsy and associated neurodevelopmental deficits, whereas rapamycinmay inhibit this process, at least in certain tissues (Wang et al., 2006; Talos et al., 2008; Li et al., 2010; Sharmaet al., 2010).”
Targeting the mTOR Signaling Network for Alzheimer’s Disease Therapy
Wang, C., Yu, J., Miao, D., Wu, Z., Tan, M., & Tan, L. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8505-8 · Cited by 142
“To complement this, blockade of mTOR completely blocks ketamine induction of synaptogenesis [119, 120].”
BackgroundZhong, P., Wang, W., Pan, B., Liu, X., Zhang, Z., Long, J. Z., Zhang, H., Cravatt, B. F., & Liu, Q.-S. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.24 · Cited by 143
“The activation of mTOR and associated increase in the synthesis of synaptic proteins contribute to rapid antidepressant action of NMDA receptor antagonist ketamine (Li et al, 2010) and group II/III mGluR antagonist LY341495 (Dwyer et al, 2012).”
BackgroundSarkar, A., & Kabbaj, M. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.12.025 · Cited by 134
“Spine density was sampled in the proximal segment [a segment known to be affected by chronic stress exposure (32)] of the apical tuft dendrites of layer V pyramidal neurons of the PL region of the mPFC.”
BackgroundMethodResultInfluentialWilkinson, S. T., Wright, D., Fasula, M. K., Fenton, L., Griepp, M., Ostroff, R. B., & Sanacora, G. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000457960 · Cited by 122
“Sub-anesthetic doses of ketamine has been shown to induce neuroplastic changes [13, 14] over periods of hours to days following exposure in rodent models.”
Loo, C. K. A., Katalinic, N., Garfield, J. B. B., Sainsbury, K., Hadži-Pavlović, D., & MacPherson, R. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.04.032 · Cited by 142
The role of mitochondria in mood disorders: from physiology to pathophysiology and to treatment
Giménez-Palomo, A., Dodd, S., Anmella, G., Carvalho, A. F., Scaini, G., Quevedo, J., Pacchiarotti, I., Vieta, E., & Berk, M. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.546801 · Cited by 140
“A number of studies have shown that some antidepressants, including fluvoxamine, fluoxetine, sertraline, paroxetine, nortriptyline, and venlafaxine, alter ETC activity in mitochondria (241, 264).”
BackgroundTargeting PI3K-AKT/mTOR signaling in the prevention of autism
Sharma, A., & Mehan, S. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105067 · Cited by 129
De Gregorio, D., Popic, J., Enns, J. P., Inserra, A., Skalecka, A., Markopoulos, A., Posa, L., Lopez-Canul, M., He, Q., Lafferty, C. K., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2020705118 · Cited by 139
“Indeed,, these effects are prevented by the intracranial administration of rapamycin (24).”
Effect of treadmill exercise on the BDNF-mediated pathway in the hippocampus of stressed rats
Fang, Z. H., Lee, C. H., Seo, M. K., Cho, H., Lee, J. G., Lee, B. J., Park, S. W., & Kim, Y. H. (2013) · Neuroscience Research · doi:10.1016/j.neures.2013.04.005 · Cited by 125
“…factor; PI3K, Phosphatidylinsitol 3-kinase; GSK-3 , Glycogen synthase kinase-3 ; mTOR, mammalian target f rapamycin; p70S6K, p70 ribosomal protein S6 kinase; SYP, synaptophysin; PSD5, postsynaptic density protein-95; NLG 1, neuroligin 1; MAPK, mitogen-activated rotein kinase; FST,…”
BackgroundInfluentialSelf-citationQu, Y., Yang, C., Ren, Q., Ma, M., Dong, C., & Hashimoto, K. (2017) · Scientific Reports · doi:10.1038/s41598-017-16060-7 · Cited by 127
Long-term safety of ketamine and esketamine in treatment of depression
Nikayin, S., Murphy, E., Krystal, J. H., & Wilkinson, S. T. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2066651 · Cited by 120
“Traditionally, it was believed that NMDA-receptor antagonism was the central mechanism of its antidepressant action [68].”
BackgroundDeletion of Glutamate Delta-1 Receptor in Mouse Leads to Aberrant Emotional and Social Behaviors
Yadav, R., Gupta, S. C., Hillman, B. G., Bhatt, J. M., Stairs, D. J., & Dravid, S. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032969 · Cited by 123
Wang, J., Chen, H.-S., Li, H.-H., Wang, H.-J., Zou, R.-S., Lu, X.-J., Wang, J., Nie, B.-B., Wu, J.-F., Li, S., et al. (2023) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2022.12.019 · Cited by 122
Repeated Ketamine Exposure Induces an Enduring Resilient Phenotype in Adolescent and Adult Rats
Parise, E. M., Alcantara, L. F., Warren, B. L., Wright, K. N., Hadad, R., Sial, O. K., Kroeck, K. G., Iñiguez, S. D., & Bolaños-Guzmán, C. A. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.04.027 · Cited by 125
“Subanesthetic doses of ketamine are thought to enhance glutamatergic signaling and dopamine release within the prefrontal cortex by reducing excitatory input into gammaaminobutyric acid–ergic neurons that subsequently leads to hyperactivity of corticolimbic pathways (59,65,66).”
The role of NMDA receptors in the pathophysiology and treatment of mood disorders
Ghasemi, M., Phillips, C., Trillo, L., Miguel, Z. D., Das, D., & Salehi, A. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.08.017 · Cited by 138
Moskal, J. R., Burch, R., Burgdorf, J. S., Kroes, R. A., Stanton, P. K., Disterhoft, J. F., & Leander, J. D. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.852536 · Cited by 131
“Interestingly, it has been shown that GSK-3b plays a key role in regulating one form of synaptic plasticity, LTD [55,56].”
BackgroundMethodGuida, F., Luongo, L., Marmo, F., Romano, R., Iannotta, M., Napolitano, F., Belardo, C., Marabese, I., D’Aniello, A., De Gregorio, D., et al. (2015) · Molecular Brain · doi:10.1186/s13041-015-0139-5 · Cited by 127
“Moreover, selective Nr2b receptor antagonists produce antidepressant effects (ketamine like) in rodent models [58] and in human subjects [59].”
BackgroundPazini, F. L., Cunha, M. P., Rosa, J. M., Colla, A. R. D. S., Lieberknecht, V., Oliveira‐Giacomelli, Á., & Rodrigues, A. L. S. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9580-9 · Cited by 140
“These synaptic proteins are subsequently inserted into the cell membrane contributing to synaptogenesis [23, 25].”
BackgroundResultInfluentialAMPA Receptor Activation–Independent Antidepressant Actions of Ketamine Metabolite (S)-Norketamine
Yang, C., Kobayashi, S., Nakao, K., Dong, C., Han, M., Qu, Y., Ren, Q., Zhang, J.-C., Ma, M., Toki, H., et al. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.05.007 · Cited by 125
Pham, T. H., Mendez-David, I., Defaix, C., Guiard, B. P., Tritschler, L., David, D. J., & Gardier, A. M. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.05.010 · Cited by 136
“Ketamine’s rapid antidepressant-like response may require an increase in mammalian Target of Rapamycin (mTOR)-dependent expression of BDNF, ultimately leading to increased synaptogenesis in rat mPFCx (Li et al., 2010).”
InfluentialMood-stabilizing drugs: mechanisms of action
Schloesser, R. J., Martinowich, K., & Manji, H. K. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2011.11.009 · Cited by 136
Höflich, A., Hahn, A., Küblböck, M., Kranz, G. S., Vanicek, T., Windischberger, C., Saria, A., Kasper, S., Winkler, D., & Lanzenberger, R. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv040 · Cited by 125
“Although research in this scientific field has focused particularly on neuroplastic properties of ketamine (Li et al., 2010, 2011), the fact that depression significantly alters thalamic functioning as revealed by fMRI studies in depressed patients (Fu et al., 2004; Dichter et al., 2009; for…”
BackgroundMammalian Reverse Genetics without Crossing Reveals Nr3a as a Short-Sleeper Gene
Sunagawa, G. A., Sumiyama, K., Ukai-Tadenuma, M., Perrin, D., Fujishima, H., Ukai, H., Nishimura, O., Shi, S., Ohno, R.-I., Narumi, R., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.052 · Cited by 128
“…the NMDAR is implicated in several psychological disorders, including schizophrenia (Belforte et al., 2010; Moghaddam and Javitt, 2012; Mohn et al., 1999), Alzheimer’s disease (Snyder et al., 2005), and depression (Autry et al., 2011; Li et al., 2010), all of which have associated sleep disorders.”
BackgroundDepression: Biological markers and treatment
Nedic Erjavec, G., Sagud, M., Nikolac Perkovic, M., Svob Strac, D., Konjevod, M., Tudor, L., Uzun, S., & Pivac, N. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110139 · Cited by 119
Dual Role of Autophagy in Diseases of the Central Nervous System
Bar-Yosef, T., Damri, O., & Agam, G. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00196 · Cited by 125
Therapeutic potential of N-methyl-D-aspartate receptor modulators in psychiatry
Hanson, J. E., Yuan, H., Perszyk, R. E., Banke, T. G., Xing, H., Tsai, M.-C., Menniti, F. S., & Traynelis, S. F. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01614-3 · Cited by 113
Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants
Gould, T. D., Zarate, C. A., & Thompson, S. M. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052811 · Cited by 133
“There is strong evidence that growth-associated signaling cascades converging on the protein mTOR are important in the responses of several rapid-acting antidepressant compounds (71).”
BackgroundNMDAR-independent, cAMP-dependent antidepressant actions of ketamine
Wray, N. H., Schappi, J. M., Singh, H., Senese, N. B., & Rasenick, M. M. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0083-8 · Cited by 123
Iafrati, J., Orejarena, M. J., Lassalle, O., Bouamrane, L., & Chavis, P. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.66 · Cited by 132
Phoumthipphavong, V., Barthas, F., Hassett, S., & Kwan, A. C. (2016) · eneuro · doi:10.1523/eneuro.0133-15.2016 · Cited by 132
“Studies of ketamine effects in animal models have found antidepressant-like behavioral responses in naive and stressed rodents (Li et al., 2010; Autry et al., 2011; Li et al., 2011; Donahue et al., 2014).”
BackgroundResultInfluentialAn update on ketamine and its two enantiomers as rapid-acting antidepressants
Zhang, K., & Hashimoto, K. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1554434 · Cited by 132
“of new spine synapses through activated the mTOR signaling pathway in the rat prefrontal cortex [54,55].”
BackgroundThe role of neurotrophins in major depressive disorder
Jiang, C., & Salton, S. (2013) · Translational Neuroscience · doi:10.2478/s13380-013-0103-8 · Cited by 113
Pearlman, D. M., & Najjar, S. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.05.001 · Cited by 124
Novel drug developmental strategies for treatment‐resistant depression
Borbély, É., Simon, M., Fuchs, E., Wiborg, O., Czéh, B., & Helyes, Z. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15753 · Cited by 106
“The pronounced recovery of synaptogenesis might mediate many of the prolonged effects (Li et al., 2010; Pryazhnikov et al., 2018), which is also supported by the fact that long-lasting beneficial actions occur hours after ketamine is eliminated from the body (Fagerholm et al., 2021; for review, see…”
BackgroundKetamine accelerates fear extinction via mTORC1 signaling
Girgenti, M. J., Ghosal, S., LoPresto, D., Taylor, J. R., & Duman, R. S. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.12.026 · Cited by 125
Self-citationVGF function in depression and antidepressant efficacy
Jiang, C., Lin, W.-J., Sadahiro, M., Labonté, B., Menard, C., Pfau, M. L., Tamminga, C. A., Turecki, G., Nestler, E. J., Russo, S. J., et al. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.233 · Cited by 124
“To determine the molecular mechanisms underlying impaired ketamine response in intrahippocampal AAV-CreGFP-injected Vgf flpflox/flpflox mice, we examined mTOR signaling and phosphorylation of AMPA receptor subunit GluR1, as both have been implicated in ketamine’s antidepressant actions 20, 28 .”
InfluentialFogaça, M. V., Wu, M., Li, C., Li, X.-Y., Picciotto, M. R., & Duman, R. S. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-00916-y · Cited by 129
Self-citationKetamine applications beyond anesthesia – A literature review
Nowacka, A., & Borczyk, M. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172547 · Cited by 129
Veenstra-VanderWeele, J., & Blakely, R. D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.185 · Cited by 128
“Further, the behavioral actions of 5-HT-elevating antidepressants have been linked to mTOR activation (Li et al, 2010) and alleles of 5HTTLPR have been found to associate with elevated aggression and destructive behavior in FraX patients (Hessl et al, 2008).”
BackgroundStamou, M., Streifel, K. M., Goines, P. E., & Lein, P. J. (2013) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2012.12.001 · Cited by 128
“BDNF modulates dendritic growth and plasticity by activating PI3K/mTOR signaling downstream of binding to the tyrosine kinase (Trk) receptors, which are members of the RTK family of transmembrane receptors (Gong et al., 2006; Jaworski et al., 2005; Kumar et al., 2005; Takei et al., 2004).”
BackgroundInfluentialGABAA receptors as targets for treating affective and cognitive symptoms of depression
Lüscher, B., Maguire, J. L., Rudolph, U., & Sibille, E. L. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.06.009 · Cited by 129
Stress, glucocorticoids and glutamate release: Effects of antidepressant drugs
Musazzi, L., Racagni, G., & Popoli, M. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2011.05.002 · Cited by 131
“…activates the mammalian target of rapamycin pathway, leading to increased synaptic signaling proteins and increased number and function of new spine synapses in the prefrontal cortex of rats, modifications opposite to the synaptic deficits that result from exposure to stress (Li et al., 2010).”
Ma, X.-C., Dang, Y.-H., Jia, M., Ma, R., Wang, F., Wu, J., Gao, C.-G., & Hashimoto, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056053 · Cited by 114
Synaptic regulation of affective behaviors; role of BDNF
Ninan, I. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.04.011 · Cited by 111
“The recent demonstration that ketamine augments the formation of new dendritic spines in the PFC further supports the potential role of structural plasticity in the regulation of affective behaviors (Li et al., 2010).”
InfluentialAction control is mediated by prefrontal BDNF and glucocorticoid receptor binding
Gourley, S. L., Swanson, A. M., Jacobs, A. M., Howell, J. L., Mo, M., DiLeone, R. J., Koleske, A. J., & Taylor, J. R. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208342109 · Cited by 118
“Moreover, we targeted deep-layer PL neurons because dendritic spine remodeling in this region is associated with the antidepressant-like effects of ketamine (27); however, our data do not support a selective role for deep-layer PL dendritic spine remodeling in CORT-induced depressive-like amotivation because GR antago…”
BackgroundMethodRapid Antidepressant Effect of Ketamine in the Electroconvulsive Therapy Setting
Abdallah, C. G., Fasula, M., Kelmendi, B., Sanacora, G., & Ostroff, R. (2012) · The Journal of ECT · doi:10.1097/yct.0b013e31824f8296 · Cited by 123
“Several recent preclinical studies have demonstrated the necessity of a ‘‘glutamate surge’’ and the accompanying AMPA activation in generating the antidepressantYlike response of ketamine and other NMDA antagonists.(26,35,36) It is hypothesized that ketamine increases glutamate release by selectively inhibiting GABAer…”
BackgroundThe receptor hypothesis and the pathogenesis of depression: Genetic bases and biological correlates
Wang, H., Wang, Z., & Chen, N. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105542 · Cited by 126
Chowdhury, G. M. I., Behar, K. L., Cho, W., Thomas, M. A., Rothman, D. L., & Sanacora, G. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.11.006 · Cited by 125
“The absence of an effect on mPFC cycling and metabolism by the higher (80 mg/kg) anesthetic dose is consistent with earlier findings showing similar anesthetic doses of ketamine not to have significant effects on glutamate efflux (7) and protein phosphorylation (17).”
New paradigms for treatment‐resistant depression
Zarate, C., Duman, R. S., Liu, G., Sartori, S., Quiroz, J., & Murck, H. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12223 · Cited by 109
Self-citationmGlu2/3 and mGlu5 receptors: Potential targets for novel antidepressants
Chaki, S., Ago, Y., Palucha-Paniewiera, A., Matrisciano, F., & Pilc, A. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.05.022 · Cited by 116
“Recent studies have shown that ketamine activates mammalian target of rapamycin (mTOR) signaling through the stimulation of AMPA receptors, and implicating mTOR signaling in the antidepressant effects of ketamine (Li et al., 2010, 2011).”
Glutamate-Based Antidepressants: Preclinical Psychopharmacology
Pilc, A., Wierońska, J. M., & Skolnick, P. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.01.021 · Cited by 126
Stress and excitatory synapses: From health to disease
Timmermans, W., Xiong, H., Hoogenraad, C. C., & Krugers, H. J. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.05.043 · Cited by 133
“Accordingly, studies in rodents show that blocking NMDA receptors using Ketamine rapidly reverses chronic stress-induced changes in spine number, synaptic function, anhedonia and anxiety (Liu and Aghajanian, 2008; Li et al., 2010, 2011).”
Baranyi, A., Amouzadeh-Ghadikolai, O., von Lewinski, D., Rothenhäusler, H., Theokas, S., Robier, C., Mangge, H., Reicht, G., Hlade, P., & Meinitzer, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160542 · Cited by 127
“As a consequence of an administration of ketamine, synaptic signalling proteins and the number and function of new spine synapses in the prefrontal cortex increased in an animal study with rats [27, 28].”
BackgroundIncreased Glutamate Levels in the Medial Prefrontal Cortex in Patients with Postpartum Depression
McEwen, A. M., Burgess, D., Hanstock, C. C., Seres, P., Khalili, P., Newman, S. C., Baker, G. B., Mitchell, N., Khudabux, J., Allen, P. S., et al. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.101 · Cited by 126
Metadata
- Authors
- Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S.
- Affiliations
- Yale University (US)
- Laboratory of Molecular Psychiatry, Center for Genes and Behavior, Departments of Psychiatry and Neurobiology, Yale University School of Medicine, 34 Park Street, New Haven, CT 06508, USA.
- Corresponding author
- Duman, Ronald S.
- Venue
- Science
- Published
- 2010-08-20
- Volume
- 329
- Issue
- 5994
- Pages
- 959-964
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3116441
- OpenAlex
- W2089351762
- Cited by
- 2,881
- References
- 14
- Citations by year
- 2026: 147 · 2025: 161 · 2024: 171 · 2023: 175 · 2022: 218 · 2021: 234 · 2020: 233 · 2019: 202 · 2018: 199 · 2017: 171 · 2016: 205 · 2015: 217 · 2014: 136 · 2013: 153 · 2012: 125
- FWCI
- 96.23
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- Funders
- National Institute of Mental Health (2P01 MH25642, MH-45481, P01MH025642, R01MH045481)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine, mTOR signaling, synaptogenesis, NMDA receptor antagonists, rapid antidepressant effects, treatment-resistant depression, prefrontal cortex, dendritic spines, mood disorders
- MeSH terms
- Animals, Antidepressive Agents, Depression, Ketamine, Male, Neurons, Neuropeptides, Phenols, Piperidines, Synapses, Time Factors, Protein Biosynthesis, Signal Transduction, Receptors, N-Methyl-D-Aspartate, Rats, Sprague-Dawley, Protein Serine-Threonine Kinases, Sirolimus, Intracellular Signaling Peptides and Proteins, Dendritic Spines, Rats, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.